- 112,000-Square-Foot Baltimore Facility Is Designed to Enable Surge Manufacturing of Medical Countermeasures to Address Urgent Public Health Threat
ADVISORY, May 09, 2017 (GLOBE NEWSWIRE) --
| WHO: | Emergent BioSolutions Inc. (NYSE:EBS) |
| WHAT: | Ribbon-cutting and tour of expanded Emergent BioSolutions’ Center for |
| Innovation in Advancement Development and Manufacturing (CIADM), | |
| featuring speakers: | |
| Daniel J. Abdun-Nabi | |
| President & Chief Executive Officer, Emergent BioSolutions | |
| Rick A. Bright, Ph.D. | |
| Director, Biomedical Advanced Research and Development Authority (BARDA) | |
| Deputy Assistant Secretary, Office of the Assistant Secretary for Preparedness | |
| and Response at the U.S. Department of Health and Human Services (HHS) | |
| William H. Cole | |
| President & CEO, Baltimore Development Corporation | |
| Secretary Mike Gill | |
| Department of Commerce, State of Maryland | |
| WHY: | Five years ago, Emergent and BARDA entered into a public-private partnership |
| to establish a CIADM intended to develop and manufacture medical | |
| countermeasures to protect the public in health emergencies. | |
| This Wednesday, Emergent will unveil its newly expanded Baltimore CIADM | |
| facility – one of only three HHS-designated Centers in the United States. The | |
| 112,000-square-foot facility, comprised of laboratory, manufacturing and office | |
| space, offers flexible manufacturing of drug substance from microbial, cell | |
| culture, or viral production platforms. Its capabilities for advanced | |
| development and manufacturing of medical countermeasures were designed to | |
| help address the U.S. government’s national security and public health needs. | |
| The facility is equipped with disposable manufacturing technology to enable | |
| Emergent to meet the government’s domestic preparedness priorities and | |
| needs on a cost-effective, reliable and sustainable basis. | |
| Since its inception, the Emergent CIADM has been awarded four task orders by | |
| BARDA to develop Ebola and Marburg therapeutics and a Zika vaccine. | |
| Emergent has also successfully manufactured some of its product candidates | |
| at the CIADM and an Ebola vaccine candidate as part of a third-party | |
| collaboration. | |
| WHERE: | Emergent BioSolutions Bayview Campus |
| 5901 East Lombard St. | |
| Baltimore, MD 21224 | |
| WHEN: | Wednesday, May 10, 2017 |
| 9 a.m. to 11 a.m. |
About Emergent BioSolutions
Emergent BioSolutions Inc. is a global life sciences company seeking to protect and enhance life by focusing on providing specialty products for civilian and military populations that address accidental, intentional, and naturally emerging public health threats. Through our work, we envision protecting and enhancing 50 million lives with our products by 2025. Additional information about the company may be found at www.emergentbiosolutions.com. Follow us @emergentbiosolu.
Media Contact: Lynn Kieffer Vice President, Corporate Communications 240-631-3391 kiefferl@ebsi.com
